CRCL adjuvant plus apoptotic tumor cells provide therapeutic effects in a pre-established tumor model.

BALB/c mice were subcutaneously injected with 2 × 10⁴(LD₁₀₀) 12B1-D1 cells at right groin on day 0. On day +1 or +3, mice were vaccinated with Mit-C–treated 12B1-D1 cells (2 × 10⁶/mouse) plus 20 μg/mouse liver–derived CRCL adjuvant by subcutaneous injection at the opposite groin. (Saline versus day 3 P = NS; saline versus day1P < .05 from day 17 onward; n = 4 mice per group. Representative data from 1 of 3 experiments are shown.)